ALS Clinic Lisbon

This ALS clinic was initiated more than 30 years ago to follow ALS patients and to investigate this disease. It is located in the main University Hospital of Lisbon, and related to the Faculty of Medicine and a research institute (iMM) – Medical Academic Center of Lisbon.

ALS Clinic Lisbon

The ALS clinic provides multidisciplinary care for ALS patients and interacts with the ALS patients Association. It is supported by the Hospital Clinical Investigation Center for accomplishing clinical trials. Investigation is integrated with the Faculty of Medicine (University of Lisbon) and Institute of Molecular Medicine-JLA (research institute) to promote clinical and translational investigation. This unit regularly follows more than 200 patients from Lisbon and other regions of the country. Every year, 50-60 new patients are observed, some from other centers and asking for diagnosis confirmation. For more than 30 years this center has a regular scientific output, including clinical features and disease progression, neurophysiology, respiratory evaluation and ventilatory support, biomarkers, genetics, epidemiology, big-data analysis and artificial intelligence, sensors, and clinical trials.

Contact
Location
Instituto De Medicina Molecular, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal

Our Specialists

Mamede de Carvalho

Professor of Physiology and Head of unit

Professor Mamede is a Neurologist and Neurophysiologist. He is a full professor […]

Mamede de Carvalho
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more